Intelligence · Clinical Development
Pipeline search results
Programs matching “oncology” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 189 pipeline programs matching "oncology" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Infigratinib
BridgeBio Oncology Therapeutics
Glioma
1 trial -
Infigratinib
BridgeBio Oncology Therapeutics
Bladder Transitional Cell Carcinoma
1 trial -
Infigratinib
BridgeBio Oncology Therapeutics
Breast Cancer
1 trial -
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Kura Oncology
Pancreatic Ductal Adeno Carcinoma, Colorectal Cancer, Non- Small Cell Lung Cancer (NSCLC), Renal Cell Carcinoma
1 trial -
KO-947
Kura Oncology
Advanced Malignant Neoplasm
1 trial -
KO-MEN-008
Kura Oncology
Relapsed and/or refractory Acute Myeloid Leukemia
1 trial -
PBTC-051
Pyxis Oncology
Glioblastoma Multiforme
1 trial -
PYX-106
Pyxis Oncology
Solid Tumor
1 trial -
PYX-201
Pyxis Oncology
Solid Tumor
1 trial -
Pembrolizumab
Cardiff Oncology
Anal Cancer Stage III A
1 trial -
Phase 1 Study of PYX-106 in Solid Tumors
Pyxis Oncology
Solid Tumors
1 trial -
Phase 1 Study of PYX-201 in Solid Tumors
Pyxis Oncology
Advanced solid tumors
1 trial -
SRF617
Coherus Oncology
Advanced Solid Tumor
1 trial -
Tipifarnib
Kura Oncology
Advanced Solid Tumor
1 trial -
Tipifarnib
Kura Oncology
NSCLC
1 trial -
Venetoclax
Kura Oncology
Acute Myeloid Leukemia
1 trial -
Ziftomenib
Kura Oncology
AML
1 trial -
Ziftomenib
Kura Oncology
KMT2A-rearranged
1 trial -
Ziftomenib
Kura Oncology
Relapsed/Refractory KMT2A-r Acute Leukemia
1 trial -
Ziftomenib
Kura Oncology
Acute Myeloid Leukemia
1 trial -
Ziftomenib
Kura Oncology
Refractory Acute Leukemia
1 trial -
[225Ac]Ac-AKY-1189 (therapeutic)
Aktis Oncology
Urothelial Carcinoma Bladder
1 trial -
[225Ac]Ac-AKY-2519 (therapeutic)
Aktis Oncology
Castration Resistant Metastatic Prostate Cancer
1 trial -
evorpacept
ALX ONCOLOGY HOLDINGS INC
Higher Risk Myelodysplastic Syndromes
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.